
Amneal Pharmaceuticals, Inc.
AMRXNASDAQHealthcareDrug Manufacturers - Specialty & Generic
前收盤價
US$17.91
+US$0.01 · +0.06%
AMRX公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Hold
Wait — insufficient conviction to act
估值
61
Undervalued
動能
67
Gaining
情緒
64
Bullish
風險韌性
66
Moderate Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
- 產業
- Drug Manufacturers - Specialty & Generic
- 部門
- Healthcare
- 總部
- US
- 執行長
- Chirag K. Patel
- 上市以來
- 2018年5月7日
- 僱員
- 8,700
市場位置
日內區間
目前US$17.91,
52週區間
目前US$17.91,
- 開盤價
- US$17.99
- 前收盤價
- US$17.90
- 成交量
- 136.55萬
- 0.72× 平均值
- 平均成交量
- 189.23萬
- 日均成交量
- 市值
- 57.19億 USD
- 貝塔
- 1.26
- 市場參考 1
- 50天平均值
- US$17.507
- 高於平均水平+2.30%
- 200天平均值
- US$14.0637
- 高於平均水平+27.35%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 63.74億 USD
- 本益比(TTM)
- 36×
- 股價淨值比(TTM)
- 173.11×
- 股價營收比(TTM)
- 1.83×
- EV/EBITDA
- 10.56×
- 盈餘收益率
- 1.82%
- 自由現金流收益率
- 6.84%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 39.32%
- 營業利益率
- 12.93%
- 淨利潤率
- 5.05%
- 股東權益報酬率
- -101.78%
- 資產報酬率
- 1.96%
- 投入資本報酬率
- 13.80%
財務健康
- 負債權益比
- 84.54×
- 流動比率
- 2.17×
- 奧特曼 Z 分數
- 2.35
- 皮奧特羅斯基 F 分數
- 7 共 9 個
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 30.19億 USD | 27.94億 USD | 23.94億 USD | 22.12億 USD | 20.94億 USD |
| 銷貨成本 | 18.83億 USD | 17.74億 USD | 15.3億 USD | 14.21億 USD | 13.25億 USD |
| 毛利 | 11.36億 USD | 10.2億 USD | 8.64億 USD | 7.91億 USD | 7.69億 USD |
| 研究與開發 | 1.86億 USD | 1.91億 USD | 1.95億 USD | 2.09億 USD | 2.1億 USD |
| 銷售、一般及管理費用 | 5.27億 USD | 4.76億 USD | 4.3億 USD | 4億 USD | 3.66億 USD |
| 營業費用 | 7.13億 USD | 7.71億 USD | 6.59億 USD | 8.86億 USD | 6.16億 USD |
| 利息支出 | 2.41億 USD | 2.59億 USD | 2.11億 USD | 1.58億 USD | 1.36億 USD |
| 折舊和攤銷 | 2.24億 USD | 2.36億 USD | 2.29億 USD | 2.4億 USD | 2.33億 USD |
| 營業利益 | 4.23億 USD | 2.49億 USD | 2.04億 USD | −9492.8萬 USD | 1.53億 USD |
| 淨利 | 7205.7萬 USD | −1.17億 USD | −8399.3萬 USD | −1.3億 USD | 1062.4萬 USD |
公司資料更新於 2026年8月24日。
財報歷史與展望
- EPS優於預期率
- 91%
- 優於預期10次、低於預期1次、符合預期0次
- 平均EPS意外幅度
- +35.72%
- 11 類似報告
- 最新每股收益結果
- 0.3
- 預估0.22 · 優於預期34.83%
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
分析師評級
第三方分析師預期可能變動,並非 GoAI 建議。
分析師目標價
平均目標
US$19.75
上漲空間 10.27%評級分佈
17項評級近期分析師行動
AMRX 訊息
AMRX同業公司
持有AMRX的ETF
報告持有此股票曝險的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR1.93億0.17%1111.89億 USD0.06%US$147.31—
Vanguard Morningstar Total Stock Market ETFVTI1.02億0.00%2.3兆 USD0.03%US$378.24—
iShares Russell 2000 ETFIWM7806.58萬0.10%816.21億 USD0.19%US$299.96—
Vanguard Morningstar Small-Cap ETFVB7391.78萬0.04%1834億 USD0.03%US$304.76—
Vanguard Morningstar Small-Cap Value ETFVBR4693.49萬0.07%683億 USD0.05%US$249.18—
Vanguard Extended Market ETFVXF3631.86萬0.04%937億 USD0.05%US$245.53—
Invesco S&P SmallCap Momentum ETFXSMO3338.89萬1.11%——US$86.05—
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2899.08萬0.17%170.31億 USD0.03%US$57.28—
iShares Core S&P Small-Cap ETFIJR- 市場價值
- 1.93億
- 重量
- 0.17%
- AUM
- 1111.89億 USD
- 費用率
- 0.06%
- 價格 / 1日
- US$147.31—
Vanguard Morningstar Total Stock Market ETFVTI- 市場價值
- 1.02億
- 重量
- 0.00%
- AUM
- 2.3兆 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$378.24—
iShares Russell 2000 ETFIWM- 市場價值
- 7806.58萬
- 重量
- 0.10%
- AUM
- 816.21億 USD
- 費用率
- 0.19%
- 價格 / 1日
- US$299.96—
Vanguard Morningstar Small-Cap ETFVB- 市場價值
- 7391.78萬
- 重量
- 0.04%
- AUM
- 1834億 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$304.76—
Vanguard Morningstar Small-Cap Value ETFVBR- 市場價值
- 4693.49萬
- 重量
- 0.07%
- AUM
- 683億 USD
- 費用率
- 0.05%
- 價格 / 1日
- US$249.18—
Vanguard Extended Market ETFVXF- 市場價值
- 3631.86萬
- 重量
- 0.04%
- AUM
- 937億 USD
- 費用率
- 0.05%
- 價格 / 1日
- US$245.53—
Invesco S&P SmallCap Momentum ETFXSMO- 市場價值
- 3338.89萬
- 重量
- 1.11%
- AUM
- —
- 費用率
- —
- 價格 / 1日
- US$86.05—
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM- 市場價值
- 2899.08萬
- 重量
- 0.17%
- AUM
- 170.31億 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$57.28—
繼續GoAI的研究
在 GoAI 中研究AMRXresearch.disclaimer











